20/20 BioResponse is a business unit of 20/20 Genesystems, Inc., a leader in medical diagnostics and biological testing since 2003. Developers of BioCheck™, 20/20 operates a CLIA certified laboratory located in Rockville Maryland and manufactures BioCheck test kits, a field diagnostic test used by hundreds of emergency response and biodetection teams worldwide.
Investment opportunities are currently available to accredited investors, family offices, private equity and venture capital firms. 20/20 GeneSystems is focused on bringing its technology to Asian markets. We welcome inquiries from investment funds focusing on biotechnology and diagnostic products with an Asian market component.